Tumor-Agnostic Treatment Heading to the Clinic?
- PMID: 37888905
- DOI: 10.1158/2159-8290.CD-ND2023-0013
Tumor-Agnostic Treatment Heading to the Clinic?
Abstract
The antibody-drug conjugate trastuzumab deruxtecan could soon be the first therapy of its kind to be approved as a tumor-agnostic treatment for HER2-mutant or -expressing tumors. However, appropriate patient selection and adverse event management will be key to maximizing its benefit.
©2023 American Association for Cancer Research.
Comment on
-
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. J Clin Oncol. 2024. PMID: 37870536 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
